Premium
A Current Approach to Statin Intolerance
Author(s) -
Tompkins R,
Schwartzbard A,
Gianos E,
Fisher E,
Weintraub H
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.84
Subject(s) - medicine , statin , myocardial infarction , clinical pharmacology , pharmacotherapy , stroke (engine) , cardiology , clinical trial , heart failure , intensive care medicine , randomized controlled trial , drug , cholesterol , revascularization , pharmacology , mechanical engineering , engineering
Statins are the first‐line pharmacotherapy for cholesterol reduction. Use of these drugs in large randomized clinical trials has consistently shown significant reductions in major vascular events, including death, myocardial infarction, stroke, and coronary revascularization. The updated guidelines for the treatment of high blood cholesterol from the American College of Cardiology/American Heart Association (ACC/AHA), will lead to an increase in the number of patients taking statins. Hence, the number of cases of statin intolerance may subsequently increase, emphasizing the need to understand and treat this important problem. Clinical Pharmacology & Therapeutics (2014); 96 1, 74–80. doi: 10.1038/clpt.2014.84